Hepion Pharmaceuticals, Inc. · OTC:HEPA
Hepion Pharmaceuticals — ContraVir Pharmaceuticals — IPO Roadshow (June 2018)
19 slides from Hepion Pharmaceuticals's IPO roadshow presentation, Jun 5, 2018
Slide 1: This presentation may contain forward-looking statements within the meaning of Section 27A of the
This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,”
Slide 2: Corporate Overview
Corporate Overview Preclinical Phase 1 Phase 2 Phase 3 TXL™ Hepatitis B Company Profile Committed to finding the right combination for a curative regimen in hepatitis B Value Drivers TXL™: Novel, target organ specific, lipid conjugate of tenofovir for treating hepatitis B Completed Phase 2a trial Co
Slide 3: Experienced Leadership
Experienced Leadership James Sapirstein, R.Ph., M.B.A Chief Executive Officer 30+ years bio/pharma experience, including Gilead Sciences, Hoffmann-La Roche and BMS Key in the development and launch of Viread® Founder of Tobira Therapeutics (acquired by Allergan for $1.7 billion) Theresa Matkovits, P
Slide 4: Scientific Advisory Board
Scientific Advisory Board Carol L. Brosgart, M.D. Special Adviser of Health Care for FIPRA International, Clinical Professor of Medicine in the Divisions of Global Health Sciences Jordan Feld, M.D., M.P.H. Clinician-scientist , Western Hospital Liver Clinic & McLaughlin-Rotman Centre for Global Heal
Slide 5: HBV Market Potential
15.4%* growth in chronic HBV patients in the U.S. through 20332 350 million chronic HBV patients worldwide1 800 thousand HBV-related deaths per year3 HBV Market Potential 1 World Health Organization 2013 2 Datamonitor 2014 3 Lozano R, et al. Lancet 2012 4 William Blair Report 2016 HBV-related ESLD o
Slide 6: Finding a Functional Cure
Reduction of viremia below threshold of detection of 95–100% with virtually no resistance Finding a Functional Cure HBV Cure Eradication of the intrahepatic replication of the virus Current Reduction in viremia >$200 billion Potential global market for a curative regimen (cumulative, over 20 years)1
Slide 7: Currently Marketed Tenofovir Compounds
First Generation Tenofovir Tenofovir Disoproxil (TDF) Brand name: Viread® Bioavailability is about 25% (fasting), with systemic exposure increased by 40% with high fat meals Light meals do not significantly impact the PK of TDF TDF is unstable and high systemic blood levels of TFV linked to kidney a
Slide 8: TXL - ContraVir's Third Generation Tenofovir
TXL™ - ContraVir’s Third Generation Tenofovir Tenofovir Exalidex (TXL™) – Target Organ (Liver) Specificity
Slide 9: Hepatitis B Portfolio Highlights
Hepatitis B Portfolio Highlights TXL™ - Direct Acting Antiviral (DAA) Highly Potent Lipid Prodrug of Tenofovir Enhanced liver targeting is expected to improve safety and drive efficacy at a lower target dose Decreased potential for renal and bone toxicity vs. Viread® (TDF) Key Milestones Achieved Ph
Slide 10: HBV Targets: Combinations Toward a Functional Cure
HBV Targets: Combinations Toward a Functional Cure Direct Acting Antivirals (DAAs) In use Polymerase Rnase H RNAi Capsid Inhibitors rcDNA-cccDNA conversion cccDNA inhibitors TXL™ Immuno- Modulatory Essential Host Functions In use Interferons In use None for HBV Therapeutic Vaccines Toll R agonists S
Slide 11: TXL De-Risked Development Asset
TXL™ De-Risked Development Asset Safety Profile Favorable Pharmacokinetics Compared to Viread® Profile consistent with target organ specificity (liver) resulting in fewer “off-target” effects Significantly lower levels of systemically circulating tenofovir in blood Potent Antiviral Activity at Lower
Slide 12: CRV431: Novel, Highly Potent Cyclophilin Inhibitor
Strong Drug Profile Best-in-class potency against HBV Widest selective index of any known CPI Addresses Key HBV Endpoints Inhibits viral entry Reduces intracellular HBV DNA Reduces HBsAg, pgRNA and HBeAg May prevent liver disease progression (e.g. fibrosis, HCC) CRV431: Novel, Highly Potent Cyclophi
Slide 13: HBV Combination Platform
HBV Combination Platform Comparison of expected additive effect versus observed synergistic effect Combining Complementary MOAs TXL™ directly inhibits HBV replication CRV431 blocks HBV from entering liver cells; interrupts viral life cycle at multiple points through interactions with host molecules
Slide 14: CRV431 and Liver Disease
CRV431 and Liver Disease Chronic HBV infection frequently leads to liver fibrosis, cirrhosis, and liver cancer (hepatocellular carcinoma; HCC) Chronic HBV infection is the leading cause of HCC (approximately 50% of HCC cases), which results in approximately 350,000 deaths globally per year1 In addit
Slide 15: In vivo Liver Disease Model - Fibrosis
In vivo Liver Disease Model - Fibrosis CRV431 tested in a non-viral NASH (non-alcoholic steatohepatitis) model in mice which replicates several stages of liver disease found in chronic HBV infection, including hepatitis (inflammation), fibrosis, and HCC Study #1: Stelic Institute (Japan) 3-week, ora
Slide 16: In vivo Liver Disease Model – Liver Cancer
In vivo Liver Disease Model – Liver Cancer CRV431 tested in a non-viral NASH model in mice which replicates several stages of liver disease found in chronic HBV infection, including hepatitis (inflammation), fibrosis, and HCC CRV431 TREATMENT ASSESSMENT OF ANTI-CANCER EFFECTS: Study: Scripps Researc
Slide 17: ContraVir Value Drivers
ContraVir Value Drivers Strategic Focus Continue to drive streamlined development of TXL™ and CRV431 as essential elements of one or more curative combinations HBV Program: TXL™ – De-risked Phase 3-Ready Asset CRV431 – Advancing into Clinical Development in the US Combination therapy has a greater c
Slide 18: Thornall Street, Edison, NJ
399 Thornall Street, 1st Floor Edison, NJ 08837
Slide 19: ContraVir
% ContraVir 399 Thornall Street, 1st Floor Edison, NJ 08837